Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731730/?tool=EBI |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841533194030022656 |
|---|---|
| author | Barbara A. Friedland Holly Gundacker Sharon L. Achilles Beatrice A. Chen Craig Hoesley Barbra A. Richardson Clifton W. Kelly Jeanna Piper Sherri Johnson Brid Devlin John Steytler Kyle Kleinbeck Bindi Dangi Chantél Friend Mei Song Barbara Mensch Ariane van der Straten Cindy Jacobson Craig W. Hendrix Jill Brown Diana Blithe Sharon L. Hiller |
| author_facet | Barbara A. Friedland Holly Gundacker Sharon L. Achilles Beatrice A. Chen Craig Hoesley Barbra A. Richardson Clifton W. Kelly Jeanna Piper Sherri Johnson Brid Devlin John Steytler Kyle Kleinbeck Bindi Dangi Chantél Friend Mei Song Barbara Mensch Ariane van der Straten Cindy Jacobson Craig W. Hendrix Jill Brown Diana Blithe Sharon L. Hiller |
| author_sort | Barbara A. Friedland |
| collection | DOAJ |
| format | Article |
| id | doaj-art-c54386faff524108a66065faa5be395a |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-c54386faff524108a66065faa5be395a2025-01-17T05:31:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01201Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology developmentBarbara A. FriedlandHolly GundackerSharon L. AchillesBeatrice A. ChenCraig HoesleyBarbra A. RichardsonClifton W. KellyJeanna PiperSherri JohnsonBrid DevlinJohn SteytlerKyle KleinbeckBindi DangiChantél FriendMei SongBarbara MenschAriane van der StratenCindy JacobsonCraig W. HendrixJill BrownDiana BlitheSharon L. Hillerhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731730/?tool=EBI |
| spellingShingle | Barbara A. Friedland Holly Gundacker Sharon L. Achilles Beatrice A. Chen Craig Hoesley Barbra A. Richardson Clifton W. Kelly Jeanna Piper Sherri Johnson Brid Devlin John Steytler Kyle Kleinbeck Bindi Dangi Chantél Friend Mei Song Barbara Mensch Ariane van der Straten Cindy Jacobson Craig W. Hendrix Jill Brown Diana Blithe Sharon L. Hiller Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development PLoS ONE |
| title | Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development |
| title_full | Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development |
| title_fullStr | Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development |
| title_full_unstemmed | Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development |
| title_short | Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development |
| title_sort | acceptability of a dapivirine levonorgestrel vaginal ring in two phase 1 trials mtn 030 ipm 041 and mtn 044 ipm 053 ccn019 implications for multipurpose prevention technology development |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731730/?tool=EBI |
| work_keys_str_mv | AT barbaraafriedland acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT hollygundacker acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT sharonlachilles acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT beatriceachen acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT craighoesley acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT barbraarichardson acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT cliftonwkelly acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT jeannapiper acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT sherrijohnson acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT briddevlin acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT johnsteytler acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT kylekleinbeck acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT bindidangi acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT chantelfriend acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT meisong acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT barbaramensch acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT arianevanderstraten acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT cindyjacobson acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT craigwhendrix acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT jillbrown acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT dianablithe acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment AT sharonlhiller acceptabilityofadapivirinelevonorgestrelvaginalringintwophase1trialsmtn030ipm041andmtn044ipm053ccn019implicationsformultipurposepreventiontechnologydevelopment |